Listed by the USPTO as VAJDA, KRISTIN ANN
Tech Center 1600 • Art Units: 1622 1624 1626
This examiner grants 84% of resolved cases
VAJDA, KRISTIN ANN handles cases in Tech Center 1600 and Art Unit 1622. The profile records 1633 resolved cases and an 83.8% allowance rate. The median time to allowance is 658 days, giving applicants a comparatively direct timing reference for planning prosecution milestones within this examiner's record.
The interview lift is 11.2%, suggesting that interviews have a limited measured association with allowance outcomes here. The listed companies are Pfizer Inc., Samsung Display Co., Ltd., and The Regents of the University of California. NIXON & VANDERHYE, PC, ALSTON & BIRD LLP, and ARENTFOX SCHIFF LLP are the listed firms. Those recurring participants can help counsel identify relevant drafting and response experience.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18702299 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | Non-Final OA | Samsung Display Co., Ltd. |
| 18287646 | THERAPY FOR ALCOHOL-RELATED LIVER DISEASE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18322819 | DONOR-ACCEPTOR-DONOR TYPE MATERIALS FOR OPTOELECTRONIC APPLICATIONS | Non-Final OA | The Regents of the University of Michigan |
| 17282319 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | Final Rejection | The University of British Columbia |
| 18700945 | COMPOSITION USED TO PREVENT OR SUPPRESS REFEEDING SYNDROME | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 18687441 | TREATMENT OF NEURODEGENERATIVE DISEASES WITH HDAC INHIBITORS | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18263772 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | Non-Final OA | LG CHEM, LTD. |
| 18701027 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | Non-Final OA | Yale University |
| 18275287 | CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE | Final Rejection | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18799659 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy83.8% of resolved applications examined by Kristin Ann Vajda were allowed (1,633 resolved cases), compared with 60.5% across Art Unit 1622 over the last five years.
This examiner's interview lift is +11.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kristin Ann Vajda took 658 days on average from filing to allowance.
Kristin Ann Vajda examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).